Generated by Codex with GPT-5

This summary covers The Economist’s April 25th, 2026 Business article listed in the contents as Trumpian psychedelics and published under the headline Altered state.

The article argues that Donald Trump’s sudden embrace of psychedelic medicines could accelerate a promising field, but in a way that exposes a deeper problem in American drug policy. Psychedelics may help treat depression, PTSD, addiction and anxiety. The issue is not whether the field deserves attention. It does. The issue is whether treatments should be pushed forward because the evidence is strong, or because they have caught the eye of the president and his circle.

The immediate trigger is strikingly informal. Joe Rogan, the podcaster, texted Trump praising ibogaine, a psychedelic drug being explored as a treatment for opioid addiction. Trump responded favorably, then quickly signed an executive order meant to boost psychedelic research and speed regulatory review. The order sent psychedelic-drug stocks higher and created a rare political opening for a field that has spent decades trying to recover from its association with the counterculture and the legal restrictions that followed.

A Real Scientific Opening

The article is careful not to dismiss psychedelics as fringe medicine. It notes that serious research into their therapeutic uses began in the mid-20th century, before the backlash of the 1960s made work much harder. Since then, the field has slowly rebuilt itself through clinical studies of compounds such as psilocybin, LSD, MDMA, ketamine and ibogaine.

There are plausible reasons for optimism. Psychedelic-assisted therapy may help some patients whose conditions have not responded to conventional treatments. Compass Pathways, for example, has tested a synthetic version of psilocybin for treatment-resistant depression and is close to submitting final data. Definium is studying a proprietary version of LSD for anxiety and depression. Other possibilities include reviving Lykos’s rejected MDMA application if better data can be produced, or accelerating a ketamine-related treatment.

For patients with severe mental illness or addiction, speed matters. Regulatory delay can mean years of untreated suffering. The article therefore treats faster approval as a legitimate goal. America’s drug-review process can be slow, expensive and risk-averse, especially for treatments that do not fit the familiar mold of a daily pill. Psychedelic therapies often combine a drug with a structured therapeutic session, making them harder to evaluate and commercialize through standard pharmaceutical channels.

The Political Shortcut

The danger is that Trump’s approach appears to place access and influence ahead of scientific procedure. The article points to the administration’s use of priority vouchers, which can speed FDA review. In principle, these tools can be useful when they direct attention to treatments with strong evidence or urgent public-health value. In practice, they can become political favors if the deciding factor is proximity to power.

Marty Makary, the head of the FDA, suggested that several psychedelic applications were imminent and that decisions could come soon. The article presents that timetable as optimistic. Some companies are near the finish line, but not all of the data are in. Moving too quickly could backfire, especially if approval looks like a presidential decree rather than a scientific judgment.

Ibogaine illustrates the risk. It is popular among some veterans and has attracted interest for opioid addiction, but it can also pose serious cardiac dangers. The article mentions a recent death at a clinic in Mexico after a patient took the drug. That does not prove ibogaine has no place in medicine, but it does show why rigorous review matters. Psychedelic treatments can be powerful, and their risks vary widely by compound, dose, patient and setting.

The article also argues that politicized approval could hurt the drugs themselves. Insurers may be reluctant to cover treatments that appear to have been waved through. Patients may distrust them. Companies that spent years collecting evidence could find their work tainted by the perception that the rules changed for political reasons. A shortcut meant to help the field could weaken its credibility.

A Broader Pattern In Drug Policy

The psychedelic order fits a larger shift in how the Trump administration handles drug approvals. The article cites Eli Lilly’s weight-loss pill, which was approved unusually quickly after the company had pleased the administration through domestic-manufacturing pledges and price concessions. That example suggests that pharmaceutical companies may increasingly see political courtship as part of the approval strategy.

This would be a bad bargain. Drugmakers already spend heavily on lobbying. If they conclude that regulatory speed depends on flattering politicians, offering investment announcements or cultivating allies in the president’s media ecosystem, resources will move away from science and toward influence. The FDA’s value lies in its reputation for evidence-based judgment. Once that reputation weakens, even good decisions become easier to doubt.

The article’s central tension is therefore practical rather than ideological. Psychedelic medicine may well deserve faster review, more research funding and a more flexible regulatory framework. But those reforms should be transparent, consistent and grounded in data. They should not depend on which treatment happens to travel through the right podcast, donor network or White House conversation.

The Takeaway

The article portrays Trump’s psychedelics push as both opportunity and warning. The opportunity is that neglected treatments for serious mental-health and addiction problems may finally receive more attention. The warning is that a politicized FDA could damage the very therapies it tries to promote.

The best outcome would be a faster, more serious approval process that still asks hard questions about safety, efficacy and clinical practice. The worst outcome would be a market in which drug companies learn that personal access can outrank evidence. Psychedelics may be ready for a more legitimate place in medicine, but legitimacy cannot be rushed into existence by executive order.